MedTrace Logo

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

Conditions

Interventions

DRUG

BG-C477

Administered intravenously.

DRUG

Tislelizumab

Administered intravenously.

DRUG

Chemotherapy

Administered in accordance with relevant local guidelines and/or prescribing information.

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • Japan
  • New Zealand
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06596473 on ClinicalTrials.gov